

REFERENCES

- [1] World Health Organization. Cancer [Internet]. 2013 [cited 2013 Oct 20]. Available from: <http://www.who.int/mediacentre/factsheets/fs297/en>
- [2] Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers*. 2010;19(8):1893-907.
- [3] Sarikapan W. Epidemiologic report of gynecologic cancer in Thailand. *J Gynecol Oncol*. 2009;20(2):81-3.
- [4] Wiangnon S, Veerakul G, Nuchprayoon I, Seksarn P, Hongeng S, Krutvecho T, et al. Childhood cancer incidence and survival 2003-2005, Thailand: study from the Thai Pediatric Oncology Group. *Asian Pac J Cancer Prev*. 2011;12(9):2215-20.
- [5] Greenberg, PL, Gordeuk V, Issaragrisil S, Siritanaratkul N, Fucharoen S, Ribeiro RC. Major hematologic diseases in the developing world-new aspects of diagnosis and management of thalassemia, malarial anemia, and acute leukemia. *Hematology Am Soc Hematol Educ Program*. 2001;2001(1):479-98.
- [6] Moore MA, Attasara P, Khuhaprema T, Le TN, Nguyen TH, Raingsey PP, et al. Cancer epidemiology in mainland South-East Asia-past, present and future. *Asian Pac J Cancer Prev*. 2010;11 Suppl 2:S67-80.
- [7] Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. *J Hematol Oncol*. 2009;2:23.
- [8] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. *CA Cancer J Clin*. 2010;60(5):277-300.

- [9] Kell J. Emerging treatments in acute myeloid leukaemia. *Expert Opin Emerg Drugs*. 2004;9(1):55-71.
- [10] Becker, H. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Blood*. 2010;116(5):788-92.
- [11] Bienz M, Ludwig M, Mueller BU, Leibundgut EO, Ratschiller D, Solenthaler M, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. *Clin Cancer Res*. 2005;11(4):1416-24.
- [12] Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. *J Hematol Oncol*. 2011;4(36):1-11.
- [13] Stone RM. Targeted agents in AML: much more to do. *Best Pract Res Clin Haematol*. 2007;20(1):39-48.
- [14] Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. *Blood*. 2010;116(24):5089-102.
- [15] Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. *Leukemia*. 2012;26(10):2176-85.
- [16] Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. *Cell*. 1991;65(7):1143-52.
- [17] Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. *Proc Natl Acad Sci USA*. 1994;91(2):459-63.
- [18] Rosnet O, Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. *Crit Rev Oncog*. 1993;4(6):595-613.

- [19] Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. *Blood*. 2002;100(5):1532-42.
- [20] Fröhling S, Schlenk RF, Breitnick J, Benner A, Kreitmeier S, Tobis, Karen, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. *Blood*. 2002;100(13):4372-80.
- [21] Lyman SD, Jacobsen SEW. C-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. *Blood*. 1998;91(4):1101-34.
- [22] Rosnet O, BÜRHING HJ, Marchetto S, Rappold I, Lavagna C, Sainty D, et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. *Leukemia*. 1996;10(2):238-48.
- [23] Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. *Clin Cancer Res*. 2009;15(13): 4263-69.
- [24] Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. *Leukemia*. 1996;10(12):1911-8.
- [25] Abu-Duhier F, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT, et al. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. *Br J Haematol*. 2001;113(4):983-8.
- [26] Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kadera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. *Blood*. 2001;97(8):2434-9.
- [27] Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kadera Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. *Blood*. 2004;103(5):1901-8.

- [28] Hemangini HV. Comprehensive FLT3 analysis in Indian acute myeloid leukaemia. *Journal of Blood & Lymph*, 2011;2:102.
- [29] Brown M, Wittwer C. Flow cytometry: principles and clinical applications in hematology. *Clin Chem*. 2000;46(8):1221-9.
- [30] Kurien BT, ScoWeld RH. Western blotting. *Methods*. 2006;38:283-93.
- [31] Santos CFd, Sakai VT, Machado MAdAM, Schippers DN, Greene AS. Reverse transcription and polymerase chain reaction: principles and applications in dentistry. *J Appl Oral Sci*. 2004;12(1):1-11.
- [32] Marvin J, Swaminathan S, Kraker G, Chadburn A, Jacobberger J, Goolsby C. Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML. *Blood*. 2011; 117(15): e120-30.
- [33] Cunliffe J, Derbyshire N, Keeler S, Coldwell R. An approach to the validation of flow cytometry methods. *Pharm Res*. 2009;26(12):2551-7.
- [34] Valentin MA, Ma S, Zhao A, Legay F, Avrameas A. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. *J Pharm Biomed Anal*. 2011;55(5):869-77.
- [35] American Cancer Society. Cancer Facts & Figures 2013 [Internet]. 2013 [cited 2013 Oct 10]. Available from: <http://www.cancer.org/acs/groups/content/@epidemiologysurveillance/documents/document/acspc-036845.pdf>
- [36] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2010;127(12):2893-917.
- [37] American Association for Cancer Research. Studies estimate the economic burden of cancer [Internet]. 2009 [cited 2013 Oct 10]. Available from:

<http://www.aacr.org/home/public--media/science-policy--government-affairs/aacr-cancer-policy-monitor/aacr-cancer-policy-monitor-january/studies-estimate-the-economic-burden-of-cancer.aspx>

- [38] Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. *Pharm Res.* 2008;25(9):2097-116.
- [39] Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med.* 2004;10(8):789-99.
- [40] Cancer Research UK. Cancer treatments [Internet]. 2013 [updated 2013 Mar 7; cited 2013 Oct 15]. Available from: <http://www.cancerresearchuk.org/cancer-help/about-cancer/treatment>
- [41] Fayed, L. Methods of treatment for cancer [Internet]. 2009 [updated 2009 Jul 29; cited 2013 Oct 15]. Available from: <http://cancer.about.com/od/treatmentoptions/a/options.htm>
- [42] Bain BJ. Leukaemia diagnosis 2010. 4th ed. New Jersey: Wiley-Blackwell; 2010. p. 1-2.
- [43] The Leukemia & Lymphoma Society. Facts 2013 [Internet]. 2009 [updated 2009 Sep 27; cited 2013 Oct 24]. Available from: <http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/generalcancer/pdf/facts.pdf>
- [44] National Cancer Institute. A Snapshot of leukemia [Internet]. 2013 [updated 2013 Mar 22; cited 2013 Nov 12]. Available from: <http://www.cancer.gov/researchandfunding/snapshots/leukemia>
- [45] Wiangnon S, editor. Leukemia. Cancer in Thailand. Bangkok: Ministry of Public Health; 2000. p. 640-6
- [46] Belson M, Kingsley B, Holmes A. Risk factors for acute leukemia in children: a review. *Environ Health Perspect.* 2007;115(1):138-45.

- [47] Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. ASH Education Program Book. 2004; 2004(1):98-117.
- [48] Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol. 2009;37(6):649-58.
- [49] Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
- [50] Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894-907.
- [51] Kuendgen A, Germing U. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. Cancer Treat Rev. 2009;35(2):97-120.
- [52] Estey EH. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol. 2006; 43(2):89-95.
- [53] Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
- [54] Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-5.
- [55] Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative Group. Br J Haematol. 1976;33(4):451-8.

- [56] Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. *J Clin Oncol*. 2003;21(24):4642-9.
- [57] The Leukemia & Lymphoma Society. AML subtypes [Internet]. 2012 [updated 2012 Sep 17; cited 2013 Nov 12]. Available from: <http://www.lls.org/diseaseinformation/leukemia/acute-myeloid-leukemia/aml-subtypes>
- [58] Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. *J Clin Oncol*. 2005;23(3):482-93.
- [59] Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. *Blood*. 1998;92(7):2322-33.
- [60] Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. *Blood Rev*. 2004;18(2):115-36.
- [61] Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. *Blood*. 2001;98(5):1312-20.
- [62] Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. *Blood*. 2010;116(13):2224-8.

- [63] Betz BL, Hess JL. Acute myeloid leukemia diagnosis in the 21st century. *Arch Pathol Lab Med*. 2010;134(10):1427-33.
- [64] Mrózek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program*. 2006;2006(1):169-77.
- [65] Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *N Engl J Med*. 2005;352(3):254-66.
- [66] Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med*. 2008;358(18):1909-18.
- [67] Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. *Hematology Am Soc Hematol Educ Program*. 2010;2010(1):47-55.
- [68] Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? *Blood*. 2007;109(2):431-48.
- [69] Kiyoi H, Naoe T. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. *Int J Hematol*. 2006;83(4):301-8.
- [70] Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. *Blood*. 2005;106(4):1154-63.
- [71] Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. *Oncogene*. 1991;6(9):1641-50.

- [72] Shurin MR, Esche C, Lotze MT. FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev. 1998;9(1):37-48.
- [73] Rosnet O, Schiff C, Pébusque MJ, Marchetto S, Tonnelle C, Toiron Y, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 1993;82(4):1110-9.
- [74] Rosnet O, Mattei MG, Marchetto S, Birnbaum D. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics. 1991;9(2):380-5.
- [75] Carow CE, Kim E, Hawkins AL, Webb HD, Griffin CA, Jabs EW, et al. Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12→q13. Cytogenet Cell Genet. 1995;70(3-4):255-7.
- [76] Maroc N, Rottapel R, Rosnet O, Marchetto S, Lavezzi C, Mannoni P, et al. Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene. 1993;8(4):909-18.
- [77] DeLapeyrière O, Naquet P, Planche J, Marchetto S, Rottapel R, Gambarelli D, et al. Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissues. Differentiation. 1995;58(5):351-9.
- [78] Lyman SD, James L, Zappone J, Sleath PR, Beckmann MP, Bird T. Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. Oncogene. 1993;8(4):815.
- [79] Brown P, Small D. FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. Eur J Cancer. 2004;40(5):707-21.
- [80] McKenna HJ. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells. Cur Opin Hematol. 2001;8(3):149-54.
- [81] McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, et al. Mice lacking flt3 ligand have deficient hematopoiesis

affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. *Blood*. 2000;95(11):3489-97.

- [82] Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. *Oncol Rev*. 2012;6(1):e8.
- [83] Lisovsky M, Braun SE, Ge Y, Takahira H, Lu L, Savchenko VG, et al. Flt3-ligand production by human bone marrow stromal cells. *Leukemia*. 1996;10(6):1012-8.
- [84] Lyman SD, James L, Johnson L, Brasel K, DeVries P, Escobar SS, et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. *Blood*. 1994;83(10):2795-801.
- [85] Lyman SD. Biology of flt3 ligand and receptor. *Int J Hematol*. 1995;62(2):63-73.
- [86] Rosnet O, Bühring HJ, DeLapeyrière O, Beslu N, Lavagna C, Marchetto S, et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. *Acta haematol*. 1996;95(3-4):218-23.
- [87] Choudhary C, Müller-Tidow C, Berdel WE, Serve H. Signal transduction of oncogenic Flt3. *Int J Hematol*. 2005;82(2):93-9.
- [88] Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. *Blood*. 1996;87(3):1089-96.
- [89] Birg F, Courcoul M, Rosnet O, Bardin F, Pébusque MJ, Marchetto S, et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. *Blood*. 1992;80(10):2584-93.
- [90] Meierhoff G, Dehmel U, Gruss HJ, Rosnet O, Birnbaum D, Quentmeier H, et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. *Leukemia*. 1995;9(8):1368-72.

- [91] Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. *Oncogene*. 2002;21(16):2555-63.
- [92] Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, Inaba J, et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. *Med pediatr Oncol*. 1999;33(6):525-9.
- [93] Xu F, Taki T, Yang HW, Hanada R, Hongo T, Ohnishi H, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. *Br J Haematol*. 1999;105(1):155-62.
- [94] Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. *Blood*. 2001;97(11):3589-95.
- [95] Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, et al. Clinical implications of FLT3 mutations in pediatric AML. *Blood*. 2006;108(12):3654-61.
- [96] Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. *Blood*. 2002;99(12):4326-35.
- [97] Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. *Leukemia*. 1997;11(10):1605-9.

- [98] Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3. A cancer and leukemia group B study. *Cancer Res.* 2001;61(19):7233-9.
- [99] Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. *Blood.* 2001;98(6):1752-9.
- [100] Spiekermann K, Bagrintseva K, Schoch C, Haferlach T, Hiddemann W, Schnittger S. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. *Blood.* 2002;100(9):3423-5.
- [101] Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. *Leukemia.* 1998;12(9):1333-7.
- [102] Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. *Oncogene.* 2000;19(5):624-31.
- [103] Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. *Blood.* 2002;99(11):3885-91.
- [104] Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. *Blood.* 2000;96(12): 3907-14.

- [105] Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. *Blood*. 2005;105(12):4792-9.
- [106] Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, et al. Essential role of signal transducer and activator of transcription (Stat) 5a but not Stat5b for Flt3-dependent signaling. *J Exp Med*. 2000;192(5):719-28.
- [107] Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. *Blood*. 2003;101(8):3164-73.
- [108] Choudhary C, Schwäble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. *Blood*. 2005;106(1): 265-73.
- [109] Zhang S, Broxmeyer HE. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. *Biochem Biophys Res Commun*. 2000;277(1):195-9.
- [110] Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, Onodera N, et al. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. *Leukemia*. 1999;13(1):38-43.
- [111] Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. *Blood*. 2001;97(1):89-94.
- [112] Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. *Cancer*. 2011;117(10):2145-55.

- [113] Rombouts WJ, Blokland I, Löwenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. *Leukemia*. 2000;14(4):675-83.
- [114] Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogossova-Agadjanyan EL, Linsley J, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. *Blood*. 2006;107(9):3724-6.
- [115] Peng HL, Zhang GS, Gong FJ, Shen JK, Zhang Y, Xu YX, et al. Fms-like tyrosine kinase (FLT) 3 and FLT3 internal tandem duplication in different types of adult leukemia: analysis of 147 patients. *Croat Med J*. 2008;49(5):650-9.
- [116] Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, et al. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. *Haematologica*. 2005;90(12):1617-25.
- [117] Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. *Blood*. 2006;107(1):293-300.
- [118] Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. *Blood*. 2004;104(4):1145-50.
- [119] Burnette WN. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. *Analytical biochemistry*. 1981;112(2):195-203.
- [120] Racaniello V. Virology toolbox: the western blot [Internet]. 2010 [cited 2013 Nov 28]. Available from: <http://www.virology.ws/2010/07/07/virology-toolbox-the-western-blot>

- [121] Rahman M. Introduction to flow cytometry [Internet]. 2006 [cited 2013 Nov 28]. Available from: <http://www.abdserotec.com/uploads/Flow-Cytometry.pdf>
- [122] Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J Mol Endocrinol*. 2000;25(2):169-93.
- [123] Food and Drug Administration. Guidance for industry: bioanalytical method validation. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. 2001.
- [124] Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. *Clin Cancer Res*. 2008;14(19):5967-76.
- [125] Lee JW, Hall M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2009;877(13):1259-71.
- [126] Lee JW. Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics. *Bioanalysis*. 2009;1(8):1461-74.
- [127] Cummings J, Ward TH, Dive C. Fit-for-purpose biomarker method validation in anticancer drug development. *Drug discov Today*. 2010;15(19):816-25.
- [128] O'Hara DM, Xu Y, Liang Z, Reddy MP, Wu DY, Litwin V. Recommendations for the validation of flow cytometric testing during drug development: II assays. *J Immunol Methods*. 2011;363(2):120-34.
- [129] Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. *Leukemia*. 2003;17(1):120-4.

- [130] Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O'Brien PJ, et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. *Pharm Res.* 2005;22(4):499-511.
- [131] Green LJ, Marder P, Ray C, Cook CA, Jaken S, Musib LC, et al. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C- β inhibitor. *Clin Cancer Res.* 2006;12(11):3408-15.
- [132] Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. *Clin Cancer Res.* 2009;15(1):267-73.
- [133] Wang L, Gaigalas AK, Marti G, Abbasi F, Hoffman RA. Toward quantitative fluorescence measurements with multicolor flow cytometry. *Cytometry A.* 2008;73(4):279-88.
- [134] Battle R, Clark B. Quantitative analysis of human leucocyte antigen expression during culture of Epstein-Barr virus-transformed cell lines using the Dako QIFIKIT. *Br J Biomed Sci.* 2007;64(1):32-4.